66.1 F
Fort Worth
Tuesday, September 22, 2020
- Advertisements -
Government FDA tentatively approves 1st drug for muscular dystrophy

FDA tentatively approves 1st drug for muscular dystrophy

Other News

Wall Street posts solid gains after surge in corporate deals

By ALEX VEIGA and DAMIAN J. TROISE AP Business Writers Wall Street kicked off the week with a broad...

Tarrant County ranks low in work-from-home study by NAR

North Texas ranks pretty high in the “Work from Home” category, according to a just-released study by the National Association of Realtors....

Commentary: Universities and COVID-19: Charting turbulent times

Ray Perryman As the COVID-19 pandemic emerged this spring, college campuses across the United States swiftly sent students...

Linear Labs introduces electric motor that will fit inside a pocket

Leading the new wave of electrification, a Fort Worth-based technology company has built an electric motor that can fit inside one's pocket,...

WASHINGTON (AP) — Federal regulators on Monday granted tentative approval to the first drug for muscular dystrophy, following an intense public campaign from patients and doctors who pushed for the largely unproven medication.

The approval comes nearly five months after the Food and Drug Administration and a panel of outside advisers panned the drug, saying there was little evidence that it helped. But regulators faced a public backlash from patients’ families, politicians and physicians.

The FDA cleared Sarepta Therapeutics’ Exondys 51 for a rare form of Duchenne muscular dystrophy, a deadly inherited disease that affects boys. It’s the first FDA approval for the degenerative condition, which causes muscle weakness, loss of movement and eventually death.

The approval was based on a company study of just 12 boys. The agency is requiring Sarepta to conduct a larger study examining whether Exondys 51 results in improved movement and function for patients. If the study fails to shows it helps, the FDA said it could withdraw the drug.

Duchenne’s muscular dystrophy is a rare disease, affecting about 1 of every 3,600 boys worldwide and usually causing death by age 25, according to the National Institutes of Health.

The new drug targets a genetic mutation that affects about 13 percent of Duchenne’s patients. Previously there were no U.S.-approved drugs to fight the disease, though steroid drugs have been used to slow the loss of muscle strength.

The FDA cleared Sarepta’s drug under its accelerated approval program, reserved for drugs that show promising early results that have not been confirmed. The drug acts on a protein called dystrophin, which plays a role in the growth of muscle fibers. The 12-patient study showed an increase in dystrophin “that is reasonably likely to predict” benefit in some patients, the FDA said in its announcement

“Accelerated approval makes this drug available to patients based on initial data, but we eagerly await learning more about the efficacy of this drug through a confirmatory clinical trial,” said Dr. Janet Woodcock, director of the FDA’s drug center.

FDA staff said at a public meeting in April that they “strongly encouraged” Sarepta to conduct a larger, more comprehensive study of its drug with a randomly selected control group of patients receiving a placebo — considered the gold standard of study design.

An outside panel of experts voted 7-3 at the meeting that the drug did not show effectiveness in treating the disease. The FDA is not required to follow the advice of its advisory panels, though it often does.

Shares of Sarepta Therapeutics jumped more than 75 percent to $21.37 in morning trading. The company is based in Cambridge, Massachusetts.

- Advertisements -
- Advertisements -

Latest News

Texas Motor Speedway to serve as polling site Nov. 3

The Lone Star Tower Condominium Clubhouse at Texas Motor Speedway will serve as a polling site for the 2020 United States presidential...

Barrett emerges as court favorite; Trump to pick by weekend

By LISA MASCARO, ZEKE MILLER and JONATHAN LEMIRE Associated PressWASHINGTON (AP) — President Donald Trump met Monday with Judge Amy Coney Barrett...

Boys & Girls Clubs Of Greater Tarrant County use club sites to register voters

Boys & Girls Clubs of Greater Tarrant County, in honor of National Voter Registration Day on Sept. 22, 2020, will be using...

Fort Worth City Council Preview for Sept. 22

City Council Work Session, 8:30 a.m., Room 290 of City Hall, 200 Texas St. Informal reports will discuss 2019...

Cuban-American judge from Florida on Trump’s high court list

By CURT ANDERSON and ADRIANA GOMEZ LICON Associated Press MIAMI (AP) — A daughter of Cuban exiles who has...